The association of plasminogen activator inhibitor (PAI-1) Level and 4G/5G Gene polymorphism with diabetic nephropathy in type 2 diabetes mellitus / Nesma Mohamed Abdelraswool ; Supervised Manal Mohamed Kamal , Mai Mohsen Fawzi , Nahed Mohamed Ibrahim

By:

Nesma Mohamed Abdelraswool

Contributor(s):

Material type: Text

TextLanguage: English Publication details: Cairo : Nesma Mohamed Abdelraswool , 2015Description: 154 P. : facsimiles ; 25cmOther title:

علاقة مستوى مثبط محفز البلازمينوجين -1 فى الدم والتعدد الشكلى للجين 4ج/5ج فى مرضى البول السكرى المصابين بالقصور الكلوى [Added title page title]

Subject(s):

Available additional physical forms:

Issued also as CD

Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology Summary: Background: Plasminogen activator inhibitor (PAI-1) is a regulatory enzyme of fibrinolytic system. Point mutation in PAI-1 is implicated in the pathogenesis of diabetic nephropathy (DN) in many ethinic groups. The aim of this study was to study the association of 4G/5G PAI-1 polymorphism as a risk factor of DN in type 2 diabetes mellitus (T2DM) patients. Subjects and Methods: The PAI-1 polymorphism was detected in 90 T2DM patients by SSP-PCR. They were divided into 2 groups: 45 patients without nephropathy, 45 patients with nephropathy. Plasma levels of PAI-1 were assayed by ELISA. Results: The genomic DNA analysis of (PAI-1) 4G/5G gene polymorphism (rs 1799889) revealed no statistically significant difference in distribution of different genotypes (P=1.0). The frequency of4G/4G genotype was (8.9 % & 11.1%), 4G/5G genotype was (48.9 % & 48.9 %) and 5G/5G genotype was (42.2% & 40%) in group I (diabetic patients without nephropathy) and group II (diabetic patients with nephropathy) respectively. Plasma levels of PAI-1 were not associated with PAI-1 mutation, also there was no significant association between PAI-1 level and DN (P=0.548). Conclusion: Plasminogen activator inhibitor-1 gene mutation was not associated with increased risk for diabetic nephropathy in type 2 diabetic patients and had no effect on plasma levels of PAI-1

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Home library	Call number	Copy number	Status	Date due	Barcode
Thesis	قاعة الرسائل الجامعية - الدور الاول	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.11.07.M.Sc.2015.Ne.A (Browse shelf(Opens below))		Not for loan		01010110069075000
CD - Rom	مخـــزن الرســائل الجـــامعية - البدروم	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.11.07.M.Sc.2015.Ne.A (Browse shelf(Opens below))	69075.CD	Not for loan		01020110069075000

Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology

Background: Plasminogen activator inhibitor (PAI-1) is a regulatory enzyme of fibrinolytic system. Point mutation in PAI-1 is implicated in the pathogenesis of diabetic nephropathy (DN) in many ethinic groups. The aim of this study was to study the association of 4G/5G PAI-1 polymorphism as a risk factor of DN in type 2 diabetes mellitus (T2DM) patients. Subjects and Methods: The PAI-1 polymorphism was detected in 90 T2DM patients by SSP-PCR. They were divided into 2 groups: 45 patients without nephropathy, 45 patients with nephropathy. Plasma levels of PAI-1 were assayed by ELISA. Results: The genomic DNA analysis of (PAI-1) 4G/5G gene polymorphism (rs 1799889) revealed no statistically significant difference in distribution of different genotypes (P=1.0). The frequency of4G/4G genotype was (8.9 % & 11.1%), 4G/5G genotype was (48.9 % & 48.9 %) and 5G/5G genotype was (42.2% & 40%) in group I (diabetic patients without nephropathy) and group II (diabetic patients with nephropathy) respectively. Plasma levels of PAI-1 were not associated with PAI-1 mutation, also there was no significant association between PAI-1 level and DN (P=0.548). Conclusion: Plasminogen activator inhibitor-1 gene mutation was not associated with increased risk for diabetic nephropathy in type 2 diabetic patients and had no effect on plasma levels of PAI-1

Issued also as CD

There are no comments on this title.

to post a comment.